Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine E Gleason

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Journal of Clinical Investigation|November 22, 2014
mTORC2 regulates renal tubule sodium uptake by promoting ENaC activityCatherine E Gleason, Gustavo Frindt, Chih-Jen Cheng, et al.
The Journal of Biological Chemistry|April 18, 2021
Role of mTORC2 in biphasic regulation of brown fat metabolism in response to mild and severe coldPrasanna K R Allu, Esther Paulo, Ambre M Bertholet, et al.
The Journal of Biological Chemistry|August 4, 2022
Interactions between mTORC2 core subunits Rictor and mSin1 dictate selective and context-dependent phosphorylation of substrate kinases SGK1 and AktZanlin Yu, Junliang Chen, Enzo Takagi, et al.
Scientific Reports|February 3, 2018
Non-invasive detection of divergent metabolic signals in insulin deficiency vs. insulin resistance in vivoCornelius von Morze, Prasanna K R Allu, Gene Y Chang, et al.
Journal of Medicinal Chemistry|February 21, 2026
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised CancersJustin A Shapiro, Nathan J Dupper, Breena Fraga-Walton, et al.
Journal of Medicinal Chemistry|August 14, 2025
Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor ActivityAndrew T Bockus, Siegfried S F Leung, Breena Fraga-Walton, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F ActivityShilpa Singh, Catherine E Gleason, Min Fang, et al.
Nature|August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitorsShilpa Singh, Catherine E Gleason, Min Fang, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Journal of Clinical Investigation|November 22, 2014
mTORC2 regulates renal tubule sodium uptake by promoting ENaC activityCatherine E Gleason, Gustavo Frindt, Chih-Jen Cheng, et al.
The Journal of Biological Chemistry|April 18, 2021
Role of mTORC2 in biphasic regulation of brown fat metabolism in response to mild and severe coldPrasanna K R Allu, Esther Paulo, Ambre M Bertholet, et al.
The Journal of Biological Chemistry|August 4, 2022
Interactions between mTORC2 core subunits Rictor and mSin1 dictate selective and context-dependent phosphorylation of substrate kinases SGK1 and AktZanlin Yu, Junliang Chen, Enzo Takagi, et al.
Scientific Reports|February 3, 2018
Non-invasive detection of divergent metabolic signals in insulin deficiency vs. insulin resistance in vivoCornelius von Morze, Prasanna K R Allu, Gene Y Chang, et al.
Journal of Medicinal Chemistry|February 21, 2026
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised CancersJustin A Shapiro, Nathan J Dupper, Breena Fraga-Walton, et al.
Journal of Medicinal Chemistry|August 14, 2025
Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor ActivityAndrew T Bockus, Siegfried S F Leung, Breena Fraga-Walton, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F ActivityShilpa Singh, Catherine E Gleason, Min Fang, et al.
Nature|August 20, 2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitorsShilpa Singh, Catherine E Gleason, Min Fang, et al.
Pageof 2